

AL SUB 5

1



W

10

15

20

25

30

A 1
cost

substituted alkynylene, or heteroalkynylene, and $-(C_1-C_8 \text{ alkylene or substituted alkylene})_{n5}-(C_3-C_{12} \text{ arylene or heteroarylene})-(C_1-C_8 \text{ alkyl or substituted alkyl})_{n6}$ where $n5$ and $n6$ are independently 0 or 1; and R_{11} , R_{11a} and R_{13} are independently selected from the group consisting of $-C_1-C_{12}$ alkyl, substituted alkyl, or heteroalkyl, $-C_1-C_{12}$ alkenyl, substituted alkenyl, or heteroalkenyl, $-C_1-C_{12}$ alkynyl, substituted alkynyl, or heteroalkynyl, and $-(C_1-C_8 \text{ alkyl or substituted alkyl})_{n7}-(C_3-C_{12} \text{ arylene or heteroarylene})-(C_1-C_8 \text{ alkyl or substituted alkyl})_{n8}$ where $n7$ and $n8$ are independently 0 or 1;


R_4 is hydrogen or $-R_{11}$ where $-R_{11}$ is as defined above; (alkyl)

n is an integer from 1 to 5;

zero or one Y is selected from the group consisting of $-O-$, $-NR_{11}-$ where R_{11} is as defined above, and $-S-$, and all remaining Y are $-CR_6R_7-$ where R_6 and R_7 are each independently selected from the group consisting of hydrogen, $-R_{14}$, $-OH$, $-OR_{14}$, $-SH$, $-SR_{14}$, $-NH_2$, $-NHR_{14}$, $-NR_{14}R_{15}$, $-C(=O)H$, $-C(=O)R_{14}$, $-C(=O)NH_2$, $-C(=O)NHR_{14}$, $-C(=O)NR_{14}R_{15}$, $-C(=O)OH$, $-C(=O)OR_{14}$, $-C(=O)SH$, $-C(=O)SR_{14}$, $-C(=O)CH_3$, $-C(=O)CH_2R_{14}$, $-C(=O)CHR_{14}R_{15}$, $-C(=O)CR_{14}R_{15}R_{16}$, $-C(=O)OCH_3$, $-C(=O)OCH_2R_{14}$, $-C(=O)OCHR_{14}R_{15}$, $-C(=O)OCR_{14}R_{15}R_{16}$, $-S(=O)_2NH_2$, $-S(=O)_2NHR_{14}$, $-S(=O)_2NR_{14}R_{15}$, $-NHC(=O)H$, $-N(R_{14})C(=O)H$, $-NHC(=O)R_{15}$, $-N(R_{14})C(=O)R_{15}$, $-NHC(=O)OR_{14}$, $-NHS(=O)_2H$, $-N(R_{14})S(=O)_2H$, $-NHS(=O)_2OR_{15}$, $-N(R_{14})S(=O)_2OR_{15}$, $-N(H)S(=O)_2R_{15}$, $-N(R_{14})S(=O)_2R_{15}$ and where two vicinal R_6 or R_7 groups combine to form a substituted or unsubstituted $-C_4-C_{10}$ cyclic alkyl, cyclic heteroalkyl, aryl or heteroaryl group where R_{14} , R_{15} and R_{16} are each independently selected from the group consisting of $-C_1-C_{12}$ alkyl, substituted alkyl, or heteroalkyl, $-C_1-C_{12}$ alkenyl, substituted alkenyl, or heteroalkenyl, $-C_1-C_{12}$ alkynyl, substituted alkynyl, or heteroalkynyl, alkoxy, and $-(C_1-C_8 \text{ alkyl or substituted alkyl})_{n9}-(C_3-C_{12} \text{ arylene or heteroarylene})-(C_1-C_8 \text{ alkyl or substituted alkyl})_{n10}$ where $n9$ and $n10$ are independently 0 or 1; or when R_{14} and R_{15} are attached to a nitrogen atom they can combine to form a substituted or unsubstituted $-C_4-C_{10}$ cyclic alkyl, cyclic heteroalkyl, aryl or heteroaryl group; or

a pharmaceutically acceptable salt thereof.

2. The compound of Claim 2 wherein R₁ is halo.
3. The compound of Claim 2 wherein R₁ is fluoro.
- 5 4. The compound of Claim 3 wherein R₂ and R₄ are hydrogen.
5. The compound of Claim 4 wherein R₃ is alkyl.
- 3 6. \ The compound of Claim 5 wherein the



group is a group of formula:




wherein:

n is 1; and


R₇ is -C(=O)NR₁₄R₁₅ where R₁₄ and R₁₅ are independently selected from the group consisting of hydrogen, -(C₁-C₁₂) alkyl, substituted alkyl, or heteroalkyl, -(C₁-C₁₂) alkenyl, substituted alkenyl, or heteroalkenyl, -(C₁-C₁₂) alkynyl, substituted alkynyl, or heteroalkynyl, alkoxy, and -(C₁-C₈ alkyl or substituted alkyl)_{n9}-(C₃-C₁₂ arylene or heteroarylene)-(C₁-C₈ alkyl or substituted alkyl)_{n10} where n₉ and n₁₀ are independently 0 or 1; or R₁₄ and R₁₅ combine to form a substituted or unsubstituted -(C₄-C₁₀)cyclic alkyl, cyclic heteroalkyl, aryl or heteroaryl group.

7. The compound of Claim 5 wherein the



A2
cost

group is a group of formula:




5 wherein:

n is 1; and


R₇ is -C(=O)NR₁₄R₁₅ where R₁₄ and R₁₅ are each independently hydrogen or -
(C₁-C₁₂) alkyl, alkoxy, aryl, heteroaryl or R₁₄ and R₁₅, when attached to the same
carbon, combine to form a cyclic heteroalkyl, aryl or heteroaryl group.

10

8. The compound of Claim 5 wherein the



group is a group of formula:



15


wherein:

n is 1; and


R₇ is -C(=O)NHR₁₅ where R₁₅ is H or -(C₁-C₁₂) alkyl, aryl, or heteroaryl or
20 -C(=O)NR₁₄R₁₅ where R₁₄ and R₁₅ form a substituted or unsubstituted -(C₄-C₁₀)cyclic
heteroalkyl.

9. The compound of Claim 5 wherein the

A2
Cost



group is a group of formula:





5 wherein:

n is 1; and

- R₇ is *n*-butylaminocarbonyl, *tert*-butylaminocarbonyl, benzylaminocarbonyl, 1,1-dimethylpropylaminocarbonyl, 2-(cyclohexen-1-yl)-ethylaminocarbonyl, indan-5-ylaminocarbonyl, 4,5-dimethylthiazol-2-ylaminocarbonyl, 4-phenoxyphenylaminocarbonyl, cyclopropylmethyl-aminocarbonyl, pyridin-2-ylaminocarbonyl, pyridin-3-ylaminocarbonyl, pyridin-4-ylmethylaminocarbonyl, morpholin-4-ylcarbonyl, 3,4-methylenedioxy-phenylaminocarbonyl, quinolin-3-ylaminocarbonyl, methylaminocarbonyl, 4-biphenylaminocarbonyl, 3-phenoxyphenylaminocarbonyl, 3,4-dichlorophenyl-aminocarbonyl, 4-*tert*-butylphenylaminocarbonyl, 4-*tert*-butylaminocarbonyl, indan-2-ylaminocarbonyl, 2,2-dimethylpropylaminocarbonyl, 4-phenylthiazol-2-ylaminocarbonyl, 5-phenylthiadiazol-2-ylaminocarbonyl, 5-ethylthiadiazol-3-ylaminocarbonyl, thiadiazol-2-ylaminocarbonyl, 3-trifluoromethoxyphenyl-aminocarbonyl, 2,5-dimethylphenylaminocarbonyl, 2,5-dimethoxyphenylamino-carbonyl, 3,4-dichlorophenylaminocarbonyl, benzthiazol-2-ylaminocarbonyl, 3-phenoxyphenylaminocarbonyl, 2-hydroxybutylaminocarbonyl, 4-hydroxybutyl-aminocarbonyl, 1,4-benzodioxan-6-ylaminocarbonyl, isoquinolin-6-ylaminocarbonyl, methylaminocarbonyl, thiazol-2-ylaminocarbonyl, 4-methylthiazol-2-yl-aminocarbonyl, 3-methylbutyl-aminocarbonyl, *n*-pentylaminocarbonyl, cyclohexylaminocarbonyl, 5-methylthiazol-2-ylaminocarbonyl, 4-methylthiazol-2-yl-aminocarbonyl, 2,4-dimethoxyphenyl-aminocarbonyl, 3,4-methylenedioxyphen-5-yl-

A2
cost

[illegible][illegible]

[illegible]
$$\begin{array}{c} R_6 R_7 \\ \diagdown \quad \diagup \\ N \\ \diagup \quad \diagdown \\ R_6 R_7 \end{array} (Y)_n$$

n is 1; and

R₇ is -C(=O)OR₁₄ where R₁₄ is hydrogen or -(C₁-C₁₂) alkyl, alkoxy, aryl, or

$$\begin{array}{c} R_6 R_7 \\ \diagdown \diagup \\ N \\ \diagup \diagdown \\ R_6 R_7 \end{array} (Y)_n$$
*N1CCCC1R7


wherein:

n is 1; and


R₇ is -C(=O)OR₁₄ where R₁₄ is alkyl; and the stereochemistry at the C₂ carbon

A2
cont

13. The compound of Claim 1 wherein the



group is a group of formula:



5


wherein:

n is 1; and


R₇ is -C(=O)NR₁₄R₁₅ where R₁₄ and R₁₅ are independently selected from the group consisting of hydrogen, -(C₁-C₁₂) alkyl, substituted alkyl, or heteroalkyl, -(C₁-C₁₂) alkenyl, substituted alkenyl, or heteroalkenyl, -(C₁-C₁₂) alkynyl, substituted alkynyl, or heteroalkynyl, alkoxy, and -(C₁-C₈ alkyl or substituted alkyl)_{n9}-(C₃-C₁₂ arylene or heteroarylene)-(C₁-C₈ alkyl or substituted alkyl)_{n10} where n₉ and n₁₀ are independently 0 or 1; or R₁₄ and R₁₅ combine to form a substituted or unsubstituted -(C₄-C₁₀)cyclic alkyl, cyclic heteroalkyl, aryl or heteroaryl group.

15

14. The compound of Claim 1 wherein the



group is a group of formula:




wherein:


n is 1; and

R₇ is -C(=O)NR₁₄R₁₅ where R₁₄ and R₁₅ are each independently hydrogen or -
(C₁-C₁₂) alkyl, alkoxy, aryl, heteroaryl or R₁₄ and R₁₅, when attached to the same
carbon, combine to form a cyclic heteroalkyl, aryl or heteroaryl group.

15. The compound of Claim 1 wherein the



group is a group of formula:




wherein:

n is 1; and


R₇ is -C(=O)NHR₁₅ where R₁₅ is H or -(C₁-C₁₂) alkyl, aryl, or heteroaryl or
-C(=O)NR₁₄R₁₅ where R₁₄ and R₁₅ form a substituted or unsubstituted -(C₄-C₁₀)cyclic
heteroalkyl.

16. The compound of Claim 1 wherein the



group is a group of formula:

A2
cont




wherein:

n is 1; and


- 5 R_7 is *n*-butylaminocarbonyl, *tert*-butylaminocarbonyl, benzylaminocarbonyl, 1,1-dimethylpropylaminocarbonyl, 2-(cyclohexen-1-yl)-ethylaminocarbonyl, indan-5-ylaminocarbonyl, 4,5-dimethylthiazol-2-ylaminocarbonyl, 4-phenoxyphenylaminocarbonyl, cyclopropylmethylaminocarbonyl, pyridin-2-ylaminocarbonyl, pyridin-3-ylaminocarbonyl, pyridin-4-ylmethylaminocarbonyl, morpholin-4-ylcarbonyl, 3,4-methylenedioxy-phenylaminocarbonyl, quinolin-3-ylaminocarbonyl, methylaminocarbonyl, 4-biphenylaminocarbonyl, 3-phenoxyphenylaminocarbonyl, 3,4-dichlorophenylaminocarbonyl, 4-*tert*-butylphenylaminocarbonyl, 4-*tert*-butylaminocarbonyl, indan-2-ylaminocarbonyl, 2,2-dimethylpropylaminocarbonyl, 4-phenylthiazol-2-ylaminocarbonyl, 5-phenylthiadiazol-2-ylaminocarbonyl, 5-ethylthiadiazol-3-ylaminocarbonyl, thiadiazol-2-ylaminocarbonyl, 3-trifluoromethoxyphenylaminocarbonyl, 2,5-dimethylphenylaminocarbonyl, 2,5-dimethoxyphenylamino-carbonyl, 3,4-dichlorophenylaminocarbonyl, benzthiazol-2-ylaminocarbonyl, 3-phenoxyphenylaminocarbonyl, 2-hydroxybutylaminocarbonyl, 4-hydroxybutylaminocarbonyl, 1,4-benzodioxan-6-ylaminocarbonyl, isoquinolin-6-ylaminocarbonyl, methylaminocarbonyl, thiazol-2-ylaminocarbonyl, 4-methylthiazol-2-ylaminocarbonyl, 3-methylbutylaminocarbonyl, *n*-pentylaminocarbonyl, cyclohexylaminocarbonyl, 5-methylthiazol-2-ylaminocarbonyl, 4-methylthiazol-2-ylaminocarbonyl, 2,4-dimethoxyphenylaminocarbonyl, 3,4-methylenedioxyphen-5-ylmethylaminocarbonyl, allylaminocarbonyl, 2-methylallylaminocarbonyl, pyrrolidin-1-ylcarbonyl, ethylaminocarbonyl, phenylaminocarbonyl, indan-1-ylaminocarbonyl, 2-methoxyethylaminocarbonyl, indan-5-ylaminocarbonyl, 3,4-difluorophenylaminocarbonyl, 5-methylisoxazol-5-ylaminocarbonyl, 3-fluorophenylaminocarbonyl, 4-fluorophenylaminocarbonyl, *N*-methyl-*N*-phenylaminocarbonyl, 2-propylaminocarbonyl, 2-phenylpropylaminocarbonyl, *n*-propylaminocarbonyl, *N*-ethyl-*N*-(*n*-

butyl)aminocarbonyl, benzylaminocarbonyl, thiazolidin-1-ylcarbonyl, piperazin-1-ylcarbonyl, piperidin-1-ylcarbonyl, azetidin-1-ylcarbonyl, homopiperdin-1-ylcarbonyl, pyrimidin-2-ylaminocarbonyl, 4-methylpiperazin-1-ylcarbonyl, 4-methylpyrimidin-2-ylaminocarbonyl, pyrimidin-4-ylaminocarbonyl, pyrazin-2-ylaminocarbonyl, imidazol-2-ylaminocarbonyl.

17. The compound of Claim 1 wherein the



group is a group of formula:




wherein:

n is 1; and

R_7 is piperidin-1-ylcarbonyl, azetidin-1-ylcarbonyl, ethylaminocarbonyl, phenylaminocarbonyl, pyrimidin-2-ylaminocarbonyl, or thiazol-2-ylaminocarbonyl;


and the stereochemistry at the C2 carbon atom of the pyrrolidine ring, i.e., carbon carrying the R_7 group is (S).

18. The compound of Claim 1 wherein the



group is a group of formula:

A2
 @ast




wherein:


n is 1; and

5 R₇ is -C(=O)OR₁₄ where R₁₄ is hydrogen or -(C₁-C₁₂) alkyl, alkoxy, aryl, or heteroaryl.

19. The compound of Claim 1 wherein the



10 group is a group of formula:



wherein:

n is 1; and

15 R₇ is -C(=O)OR₁₄ where R₁₄ is alkyl; and the stereochemistry at the C₂ carbon atom of the pyrrolidine ring is (S).

20. The compound of Claim 13-19 wherein R₂ and R₄ are hydrogen.

20 21. The compound of Claim 20 wherein R₁ is halo.

22. The compound of Claim 21 wherein R₃ is alkyl.

23. The compound of Claim 22 wherein R₁ is fluoro.


25 24. The compound of Claim 22 wherein R₃ is *n*-butyl.

Sub
A3


25. The compound of Claim 13-19 wherein R₁ is halo. ✓
26. The compound of Claim 25 wherein R₁ is fluoro and R₂ and R₄ are hydrogen.
- 5
27. The compound of Claim 26 wherein R₃ is alkyl.
28. The compound of Claim 19 wherein R₁ is hydroxy.
- 10
29. The compound of Claim 28 wherein R₃ is alkyl.
30. The compound of Claim 29 wherein R₃ is *n*-butyl.
31. The compound of Claim 1 wherein R₁ is hydroxy.
- 15
32. The compound of Claim 31 wherein R₂ and R₄ are hydrogen and R₃ is alkyl.

Sub
A4

33. The compound of Claim 31 wherein the



- 20 group is a group of formula:




wherein:

n is 1; and


- R₇ is -C(=O)NR₁₄R₁₅ where R₁₄ and R₁₅ are independently selected from the
- 25 group consisting of hydrogen, -(C₁-C₁₂) alkyl, substituted alkyl, or heteroalkyl, -(C₁-C₁₂) alkenyl, substituted alkenyl, or heteroalkenyl, -(C₁-C₁₂) alkynyl, substituted alkynyl, or heteroalkynyl, alkoxy, and -(C₁-C₈ alkyl or substituted alkyl)_{n9}-(C₃-C₁₂ arylene or heteroarylene)-(C₁-C₈ alkyl or substituted alkyl)_{n10} where *n*₉ and *n*₁₀ are independently 0 or 1; or R₁₄ and R₁₅ combine to form a substituted or unsubstituted -
- 30 (C₄-C₁₀)cyclic alkyl, cyclic heteroalkyl, aryl or heteroaryl group.

A4
cont

34. The compound of Claim 31 wherein the



group is a group of formula:



5


wherein:

n is 1; and


R₇ is -C(=O)NR₁₄R₁₅ where R₁₄ and R₁₅ are each independently hydrogen or -
(C₁-C₁₂) alkyl, alkoxy, aryl, heteroaryl or R₁₄ and R₁₅, when attached to the same
carbon, combine to form a cyclic heteroalkyl, aryl or heteroaryl group.

10

35. The compound of Claim 31 wherein the



group is a group of formula:




15

wherein:


n is 1; and

R_7 is $-C(=O)NHR_{15}$ where R_{15} is H or $-(C_1-C_{12})$ alkyl, aryl, or heteroaryl or $-C(=O)NR_{14}R_{15}$ where R_{14} and R_{15} form a substituted or unsubstituted $-(C_4-C_{10})$ cyclic heteroalkyl.

36. The compound of Claim 31 wherein the



group is a group of formula:




wherein:


n is 1; and

R_7 is *n*-butylaminocarbonyl, *tert*-butylaminocarbonyl, benzylaminocarbonyl, 1,1-dimethylpropylaminocarbonyl, 2-(cyclohexen-1-yl)-ethylaminocarbonyl, indan-5-ylaminocarbonyl, 4,5-dimethylthiazol-2-ylaminocarbonyl, 4-phenoxyphenylaminocarbonyl, cyclopropylmethyl-aminocarbonyl, pyridin-2-ylaminocarbonyl, pyridin-3-ylaminocarbonyl, pyridin-4-ylmethylaminocarbonyl, morpholin-4-ylcarbonyl, 3,4-methylenedioxy-phenylaminocarbonyl, quinolin-3-ylaminocarbonyl, methylaminocarbonyl, 4-biphenylaminocarbonyl, 3-phenoxyphenylaminocarbonyl, 3,4-dichlorophenyl-aminocarbonyl, 4-*tert*-butylphenylaminocarbonyl, 4-*tert*-butylaminocarbonyl, indan-2-ylaminocarbonyl, 2,2-dimethylpropylaminocarbonyl, 4-phenylthiazol-2-ylaminocarbonyl, 5-phenylthiadiazol-2-ylaminocarbonyl, 5-ethylthiadiazol-3-ylaminocarbonyl, thiadiazol-2-ylaminocarbonyl, 3-trifluoromethoxyphenyl-aminocarbonyl, 2,5-dimethylphenylaminocarbonyl, 2,5-dimethoxyphenylamino-carbonyl, 3,4-dichlorophenylaminocarbonyl, benzthiazol-2-ylaminocarbonyl, 3-


| Year | 1960 | 1961 | 1962 | 1963 | 1964 | 1965 | 1966 | 1967 | 1968 | 1969 | 1970 | 1971 | 1972 | 1973 | 1974 | 1975 | 1976 | 1977 | 1978 | 1979 | 1980 | 1981 | 1982 | 1983 | 1984 | 1985 | 1986 | 1987 | 1988 | 1989 | 1990 | 1991 | 1992 | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | 2050 | 2051 | 2052 | 2053 | 2054 | 2055 | 2056 | 2057 | 2058 | 2059 | 2060 | 2061 | 2062 | 2063 | 2064 | 2065 | 2066 | 2067 | 2068 | 2069 | 2070 | 2071 | 2072 | 2073 | 2074 | 2075 | 2076 | 2077 | 2078 | 2079 | 2080 | 2081 | 2082 | 2083 | 2084 | 2085 | 2086 | 2087 | 2088 | 2089 | 2090 | 2091 | 2092 | 2093 | 2094 | 2095 | 2096 | 2097 | 2098 | 2099 | 2100 |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| 1960 | 1961 | 1962 | 1963 | 1964 | 1965 | 1966 | 1967 | 1968 | 1969 | 1970 | 1971 | 1972 | 1973 | 1974 | 1975 | 1976 | 1977 | 1978 | 1979 | 1980 | 1981 | 1982 | 1983 | 1984 | 1985 | 1986 | 1987 | 1988 | 1989 | 1990 | 1991 | 1992 | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | 2050 | 2051 | 2052 | 2053 | 2054 | 2055 | 2056 | 2057 | 2058 | 2059 | 2060 | 2061 | 2062 | 2063 | 2064 | 2065 | 2066 | 2067 | 2068 | 2069 | 2070 | 2071 | 2072 | 2073 | 2074 | 2075 | 2076 | 2077 | 2078 | 2079 | 2080 | 2081 | 2082 | 2083 | 2084 | 2085 | 2086 | 2087 | 2088 | 2089 | 2090 | 2091 | 2092 | 2093 | 2094 | 2095 | 2096 | 2097 | 2098 | 2099 | 2100 | |



20



group is a group of formula:




wherein:

25

R₇ is piperidin-1-ylcarbonyl, azetidin-1-ylcarbonyl, ethylaminocarbonyl, phenylaminocarbonyl, pyrimidin-2-ylaminocarbonyl, or thiazol-2-ylaminocarbonyl;


and the stereochemistry at the C2 carbon atom of the pyrrolidine ring, i.e., carbon carrying the R₇ group is (S).

38. The compound of Claim 31 wherein the



5

group is a group of formula:




wherein:

n is 1; and


10 R₇ is -C(=O)OR₁₄ where R₁₄ is hydrogen or -(C₁-C₁₂) alkyl, alkoxy, aryl, or heteroaryl.

39. The compound of Claim 31 wherein the



15

group is a group of formula:



20 wherein:

n is 1; and

A4
Cost

~~R₇ is -C(=O)OR₁₄ where R₁₄ is alkyl; and the stereochemistry at the C₂ carbon atom of the pyrrolidine ring is (S).~~

40. The compound of Claim 32-38 wherein R₃ is *n*-butyl.

5 41. The compound of Claim 13-19 wherein R₂ and R₄ are hydrogen.

42. The compound of Claim 41 wherein R₁ is hydroxy.

10 43. The compound of Claim 42 wherein R₃ is alkyl.

44. The compound of Claim 41 wherein R₃ is *n*-butyl.

45. The compound of Claim 1 selected from the group consisting of:

15 *N*-hydroxy-3-[(*S*)-(n-butyl)-3-(2-(*S*)-1,1-dimethylethyloxycarbonyl)-pyrrolidin-1-carbonyl]-2-(*S*)-fluoropropionamide;

20 *N*-hydroxy-3-[(*S*)-(n-butyl)-3-(2-(*S*)-pyridin-1-ylcarbonyl)pyrrolidin-1-carbonyl]-2-(*S*)-fluoropropionamide;

25 *N*-hydroxy-3-[(*S*)-(n-butyl)-3-(2-(*S*)-azetidin-1-ylcarbonyl)-pyrrolidin-1-carbonyl]-2-(*S*)-fluoropropionamide;

N-hydroxy-3-[(*S*)-(n-butyl)-3-(2-(*S*)-ethylaminocarbonyl)pyrrolidin-1-carbonyl]-2-(*S*)-fluoropropionamide;

N-hydroxy-3-[(*S*)-(n-butyl)-3-(2-(*S*)-phenylaminocarbonyl)-pyrrolidin-1-carbonyl]-2-(*S*)-hydroxypropionamide;

30 *N*-hydroxy-3-[(*S*)-(n-butyl)-3-(2-(*S*)-pyrimidin-2-ylaminocarbonyl)pyrrolidin-1-carbonyl]-2-(*S*)-hydroxypropionamide; and

35 *N*-hydroxy-3-[(*S*)-(n-butyl)-3-(2-(*S*)-thiazol-2-ylaminocarbonyl)-pyrrolidin-1-carbonyl]-2-(*S*)-fluoropropionamide.

46. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claims 1-45 and a pharmaceutically acceptable excipient.

40 47. A method of treatment of a disease in a mammal treatable by administration of a peptidyl deformylase inhibitor which method comprises administration of a

(any disease)

pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1-45 and a pharmaceutically acceptable excipient.

48. The method of Claim 47 wherein the disease is a bacterial disease.

5

11/20/2009 10:00:00 AM